Endothelin expression and responsiveness in human ovarian carcinoma cell linesMORAITIS, S; LANGDON, S. P; MILLER, W. R et al.European journal of cancer (1990). 1997, Vol 33, Num 4, pp 661-668, issn 0959-8049Article

Steroid hormones and cancer : (II) lessons from experimental systemsMILLER, W. R; LANGDON, S. P.European journal of surgical oncology. 1997, Vol 23, Num 1, pp 72-83, issn 0748-7983Conference Paper

Steroid hormones and cancer : (III) Observations from human subjectsMILLER, W. R; LANGDON, S. P.European journal of surgical oncology. 1997, Vol 23, Num 2, pp 163-177, issn 0748-7983Article

Correlation between the molecular weight and potency of polar compounds which induce the differentiation of HL-60 human promyelocytic leukemia cellsLANGDON, S. P; HICKMAN, J. A.Cancer research (Baltimore). 1987, Vol 47, Num 1, pp 140-144, issn 0008-5472Article

Inhibition of cell signalling pathwaysLANGDON, S. P; SMYTH, J. F.Cancer treatment reviews. 1995, Vol 21, Num 1, pp 65-89, issn 0305-7372Article

Correlation between the molecular weight and potency of polar compounds which induce the differentiation of HL-60 human promyelocytic leukemia cellsLANGDON, S. P; HICKMAN, J. A.Cancer research (Baltimore). 1987, Vol 47, Num 1, pp 140-144, issn 0008-5472Article

Transforming growth factor-β isoform expression in human ovarian tumoursBARTLETT, J. M; LANGDON, S. P; SCOTT, W. N et al.European journal of cancer (1990). 1997, Vol 33, Num 14, pp 2397-2403, issn 0959-8049Article

Processing of the neuropeptide growth factor antagonist [Arg⁶, D-Trp^7,9, NmePHE⁸]-substance P (6-11) by a small cell lung cancer cell line (H69)CUMMINGS, J; MACLELLAN, A. J; LANGDON, S. P et al.Biochemical pharmacology. 1995, Vol 49, Num 11, pp 1709-1712, issn 0006-2952Article

12-O-tetradecanoylphorbol 13-acetate induced differentiation in human lung squamous carcinoma cellsRABIASZ, G. J; LANGDON, S. P; ANDERSON, L et al.British journal of cancer. 1992, Vol 66, Num 3, pp 439-443, issn 0007-0920Article

Investigations of the relationship between cell proliferation and differentiation of HL-60 cells induced to differentiate by N-methylformamideLANGDON, S. P; RICHARDS, F. M; HICKMAN, J. A et al.Leukemia research. 1988, Vol 12, Num 3, pp 211-216, issn 0145-2126Article

Experimental antitumor activity against murine tumor model systems of 8-carbamoy-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (mitozolomide), a novel broad-spectrum agentHICKMAN, J. A; STEVENS, M. F. G; GIBSON, N. W et al.Cancer research (Baltimore). 1985, Vol 45, Num 7, pp 3008-3013, issn 0008-5472Article

The mechanism of action of kahalalide F : Variable cell permeability in human hepatoma cell linesSEWELL, J. M; MAYER, I; LANGDON, S. P et al.European journal of cancer (1990). 2005, Vol 41, Num 11, pp 1637-1644, issn 0959-8049, 8 p.Article

Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ('Iressa')SEWELL, J. M; MACLEOD, K. G; RITCHIE, A et al.British journal of cancer. 2002, Vol 86, Num 3, pp 456-462, issn 0007-0920Article

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancerMCPHILLIPS, F; MULLEN, P; MONIA, B. P et al.British journal of cancer. 2001, Vol 85, Num 11, pp 1753-1758, issn 0007-0920Article

Inhibition of transforming growth factor α (TGF-α)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868SIMPSON, B. J. B; BARTLETT, J. M. S; LANGDON, S. P et al.British journal of cancer. 1999, Vol 79, Num 7-8, pp 1098-1103, issn 0007-0920Article

Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogenLANGDON, S. P; GABRA, H; BARTLETT, J. M. S et al.Clinical cancer research. 1998, Vol 4, Num 9, pp 2245-2251, issn 1078-0432Article

Characterization of the deamidase enzyme responsible for the metabolism of the anti-cancer peptide : H-Arg-D-Trp-N^mePhe-D-Trp-Leu-Met-NH₂JONES, D. A; CUMMINGS, J; LANGDON, S. P et al.Biochemical pharmacology. 1995, Vol 50, Num 5, pp 585-590, issn 0006-2952Article

The regulation of growth and protein expression by estrogen in vitro : a study of 8 human ovarian carcinoma cell linesLANGDON, S. P; HIRST, G. L; MILLER, E. P et al.Journal of steroid biochemistry and molecular biology. 1994, Vol 50, Num 3-4, pp 131-135, issn 0960-0760Article

The South Dakota reburial program and the discovery of a possible prehistoric dwarfLANGDON, S. P; WILLEY, P; CUMMINS, R. W et al.Plains Anthropologist. 1993, Vol 38, Num 145, pp 271-281, issn 0032-0447Article

Transforming growth factor-β mRNA expression and growth control of human ovarian carcinoma cellsBARTLETT, J. M. S; RABIASZ, G. J; SCOTT, W. N et al.British journal of cancer. 1992, Vol 65, Num 5, pp 655-660, issn 0007-0920Article

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancerSIMS, A. H; ZWEEMER, Ajm; LANGDON, S. P et al.British journal of cancer. 2012, Vol 106, Num 11, pp 1779-1789, issn 0007-0920, 11 p.Article

A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of SykKATZ, E; DUBOIS-MARSHALL, S; LANGDON, S. P et al.British journal of cancer. 2010, Vol 103, Num 3, pp 401-410, issn 0007-0920, 10 p.Article

Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastasesAITKEN, S. J; THOMAS, J. S; LANGDON, S. P et al.Annals of oncology. 2010, Vol 21, Num 6, pp 1254-1261, issn 0923-7534, 8 p.Article

The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenograftsBREISTØL, K; HENDRIKS, H. R; BERGER, D. P et al.European journal of cancer (1990). 1998, Vol 34, Num 10, pp 1602-1606, issn 0959-8049Conference Paper

Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing miceCUMMINGS, J; LANGDON, S. P; RITCHIE, A. A et al.Annals of oncology. 1996, Vol 7, Num 3, pp 291-296, issn 0923-7534Article